64Cu-Bevacizumab as a better PET imaging agent in detecting breast cancer in MDA-MB-231 orthotopic and bone metastasis mice model compared to 18FDG

Authors

Keya De Mukhopadhyay
Ting-Tung Chang, Department of Radiology, UT Health San Antonio, Texas, USA
William Phillips
Lu-Zhe Sun
Beth Goins

Abstract

Developing new imaging agents help in the detection of breast cancer with better sensitivity and specificity and it improves the patient outcomes significantly. This provides the physicians with improved early detection of breast cancer during the routine screening process and has the potential to help the surgeons in identifying the tumor margins more accurately for surgical resection. In this study, we evaluate the efficiency of ⁶⁴Cu-bevacizumab to successfully detect the small tumors (5mm), large tumors (15mm) and metastatic sites in MDA-MB-231 breast cancer mouse models compared to ¹⁸FDG and conclude that ⁶⁴Cu-bevacizumab is a promising PET (positron emission tomography) imaging agent with high possibility to be applied to human breast cancer detection, and could significantly improve patient survival.

Recommended Citation

De Mukhopadhyay, Keya; Chang, Ting-Tung; Phillips, William; Sun, Lu-Zhe; and Goins, Beth (2024) "64Cu-Bevacizumab as a better PET imaging agent in detecting breast cancer in MDA-MB-231 orthotopic and bone metastasis mice model compared to 18FDG," American Journal of Applied Bio-Technology Research (AJABTR): Vol. 2, Article 4.
Available at: https://research.smartsociety.org/ajabtr/vol2/iss2/4